Sector News

Top U.S. execs flee Ranbaxy as Sun Pharma merger looms: paper

October 13, 2014
Life sciences
Ranbaxy Laboratories has been a steady source of bad news over the past several years. And now that India-based rival Sun Pharmaceuticals is preparing to take over, the company’s top U.S. leadership is throwing in the towel.
 
According to the Indian newspaper, Business Standard, up to a half-dozen of the company’s U.S. execs are headed for the door, with country chief Venkatachalam Krishnan among them. Citing unnamed sources, the paper says department heads in finance, legal, sales and distribution have also turned in their resignations.
 
Sun Pharma agreed to buy Ranbaxy in April in a $4 billion deal and awaits regulatory approval for closing the deal. As the buyout was announced, sources started chattering that Sun would phase out the Ranbaxy brand in the U.S. Sun was also said to be planning to oust plant managers who had presided over serious manufacturing violations that landed Ranbaxy in hot water repeatedly since 2009.
 
It’s clear that Sun will have its hands full dealing with Ranbaxy’s checkered regulatory history. Four facilities are operating under a consent decree with the FDA, and the Department of Justice has issued a subpoena for information on a plant in Toansa, India, previously banned by the FDA. Sun will also have to deal with at least one state government investigation into Ranbaxy’s potential Medicaid overcharges.
 
Meanwhile, Sun has racked up its own series of recalls since announcing it would buy Ranbaxy. The company had announced three recalls by June, and an FDA warning letter chided Sun for dirty facilities, data-manipulation problems, and lax quality control, similar to the infractions that snagged Ranbaxy.
 
This wouldn’t be the first exodus from Ranbaxy in recent months. As the Business Standard points out, global quality chief Dale Adkisson and global HR head Sandeep Girotra said their goodbyes recently.
 
By Tracy Staton
 

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach